upgrad ow pt includ
tafasitamab base case primari driver
new pt see sever pipelin catalyst next
month could drive higher believ modest
expect head catalyst creat attract
move ow pt share trade ytd vs
ibb signific portion pressur relat broader
sell-off macro concern recent week current trade
given view base busi worth
appear in-lin investor view believ current level impli
pipelin valu believ significantli higher risk-adjust
fundament valu embed within late-stag pipelin
particularli given tafasitamab deal morphosi announc
januari current appear overlook strong phiii ruxolitinib
cream data announc atop dermat februari addit sever key
pipelin catalyst expect throughout believ investor
expect remain modest result believ current level provid
attract set-up entri point detail review
valuat insid
recent tafasitamab partnership add valuat
announc partnership morphosi januari antibodi
tafasitamab bla submit tafasitamab base result
phii l-mind studi evalu tafasitamab lenalidomid r/r
dlbcl target action date set regulatori
submiss europ also anticip addit develop
underway phiii b-mind studi r/r dlbcl phi first-mind
studi dlbcl kol feedback l-mind data tafasitamab
prospect commun treatment set highli posit
lead us incorpor tafasitamab valuat current estim peak
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
risk-adjust global sale r/r dlbcl contribut
valu account share econom incyt
morphosi addit believ phi first-mind data
repres key catalyst tafasitamab front-lin set
estim could valu addit brief dlbcl
primer view tafasitamab data dlbcl competit consider
revenu build insid
risk/reward appear skew upsid head catalyst
believ investor found set-up challeng late earli
advanc two key phiii readout close proxim
true-ad item clear investor expect remain
catalyst appear modest believ set-up improv
significantli full catalyst calendar howev
await manag commentari impact may
jakafi sale catalyst schedul jakafi sale social
distanc measur may neg impact new patient start mf
pv particularli would expect dramat impact given jakafi
repres core treatment symptomat patient catalyst
believ key area investor look understand potenti
disrupt tafasitamab regulatori timelin pemigatinib phii bladder
cancer data nda submiss rux cream ad
regulatori timelin tafasitamab appear on-track base case
conserv current assum month commerci delay
 europ pemigatinib rux cream delay ww
launch full year account potenti relat delay worst-
case scenario seem unlik neg impact dcf would
result possibl could face short-term
pressur relat impact manag commun
believ modest pipelin valu current embed suffici
discount disrupt
detail rux cream data earn repres next key
catalyst detail phiii rux cream data present sunday
revolution atop dermat virtual confer
manag discuss result investor call monday
previou take top line data investor debat persist
sale potenti rux cream anticip /- move
base data believ area focu detail data includ
time respons safeti patient baselin characterist beyond rux cream
await earn would expect manag provid clariti
impact
current commerci jakafi ruxolitinib myelofibrosi mf
polycythemia vera pv two type blood cancer graft-versus-host diseas
gvhd common complic stem cell transplant market jakafi
 novarti cover mark purcel commerci jakafi ex-u
earn royalti ex-u sale jakafi gener sale
manag guid peak jakafi sale prior patent
expir believ upper end guidanc rang achiev
assum modest patient volum growth current forecast peak jakafi
sale
 patient jakafi mse
 jakafi sale primari driver base busi valu estim
 sale worth addit contributor base busi valuat
royalti receiv ex-u jakafi sale cash value-per-share
royalti receiv lilli cover david rising rheumatoid
arthriti therapi olumi baricitinib estim ex-u jakafi royalti cash
olumi royalti worth aggreg total base busi
valu base investor convers believ estim
gener in-lin investor view compani base busi worth
develop broad pipelin across oncolog dermatolog current
valu late-stag pipelin program risk-adjust basi also assign aggreg
credit early-stag pipelin outlin
ruxolitinib cream tafasitamab current two largest driver late-stag
pipelin valu model summar key aspect revenu build
program
probabl
popul launch
base busi valuat combin pipelin valuat off-set
broader corpor spend alloc specif
commerci pipelin program arriv price target
note categori includ pemigatinib parsaclisib iclusig early-stag pipelin off-set broader corpor spend
throughout expect investor focu gravit toward ruxolitinib cream
tafasitamab regulatori mileston program approach mid-lat
well phii pemigatinib bladder cancer data addit area interest
believ could emerg jakafi life cycl extens program phi data
tafasitamab dlbcl assum updat provid in-lin prior guidanc
posit readout path forward area could present addit
upsid beyond current base case estim jakafi tafasitamab
diffus larg b-cell lymphoma dlbcl common aggress form non-
hodgkin lymphoma nhl refer group cancer origin white
blood cell gener bone marrow term lymphocyt three categori
lymphocyt b-cell t-cell natur killer nk cell form nhl
b-cell lymphoma pathogenesi dlbcl driven b-cell turn malign
due certain molecular alter impact b-cell matur key gene
alter implic develop dlbcl includ
myc gene
estim new case dlbcl diagnos everi year
base data nation cancer institut surveil epidemiolog end
result program nci seer dlbcl surviv rate
surviv gener increas lower age stage diseas diagnosi addit
nci seer data indic yearli incid dlbcl gener
trend downward slightli sinc earli surviv increas
death rate decreas time period
dlbcl begin within outsid lymph node follow clinic evalu
definit diagnosi typic made base result biopsi either portion
tumor incision biopsi entir tumor excision biopsi dlbcl
aris de novo transform previous indol lymphoma dlbcl
heterogen diseas evalu cancer cell surfac protein
genet test conduct defin patient cancer subtyp identifi genet
alter may impact diseas prognosi assess prognosi also base
ann arbor stage system classifi dlbcl stage i-iv base
spread diseas intern prognost index score system
evalu patient risk base age lactat dehydrogenas ldh level
perform statu diseas stage number extranod site
dlbcl subtyp determin evalu cancer cell surfac protein
two broad subtyp diseas gcb germin center b-cell non-gcb
subtyp studi date indic patient newli diagnos dlbcl patient
gcb subtyp tend superior outcom respons standard-of-car
soc treatment vs patient non-gcb subtyp addit case dlbcl
myc and/or gene overexpress and/or gene rearrang
observ poorer outcom versu counterpart lack alter
refer case doubl expressor lymphoma del double-hit/triple-hit
lymphoma dhl/thl collect refer high grade b-cell lymphoma hgbl
depend specif alter present hgbl gener poorer prognosi
versu del associ wors outcom dlbcl patient
neither del hgbl schemat dlbcl classif provid overal
diseas classif help provid patient understand gener diseas
prognosi risk use pointedli drive treatment decis none
major treatment option dlbcl target certain subtyp molecular
diffus larg b-cell lymphoma updat diagnosi risk stratif treatment yang liu stefan klau barta hematol
standard-of-car soc treatment dlbcl chemoimmunotherapi
regimen r-chop consist antibodi rituximab chemotherapi
agent cyclophosphamid doxorubicin hydrochlorid vincristin steroid
prednisolon format treatment administ vari patient
r-chop typic administ cycl patient typic receiv
cycl regimen vast major patient elig r-chop
deriv regimen base review relev literatur feedback
kol estim cure rate r-chop assum incid
mean r-chop cure patient diagnos per year
addit recent kol feedback literatur review suggest
patient relaps follow r-chop typic month
treatment r-chop
patient surviv year follow diagnosi unlik relaps
radiat therapi use frequent stage i/ii diseas vs stage iii/iv
diseas often use conjunct chemotherapi larg tumor
patient gcb-subtyp dlbcl typic best respons r-chop
non-gcb/abc subtyp patient tend rapid relaps gcb
subtyp patient patient double-hit/triple-hit diseas often
experi aggress rapid relaps within six month
patient r-chop provid cure next
option consid high-dos chemotherapi hdc follow stem cell transplant
sct typic autolog asct case use twin howev r/r
dlbcl patient elig hdc asct factor drive elig includ
cancer sensit chemotherapi abil collect enough stem cell
patient blood marrow patient gener health abil undergo
sct procedur research indic half dlbcl patient elig
hdc asct furthermor appear half patient receiv hdc asct
achiev cure diseas therefor use approxim newli
diagnos patient cure r-chop treatment estim addit
patient overal cure via hdc asct result estim
patient cure treatment r-chop and/or hdc asct
patient r/r treatment r-chop relaps
follow inelig hdc asct subsequ treatment depend patient-
specif factor includ sensit cancer chemotherapi well
diseas subtyp molecular featur consider note
patient relaps follow durabl respons initi chemotherapy-
base regimen second chemotherapy-bas regimen may tri howev
treatment option would like sought
btk inhibitor ibrutinib lenalidomid may use non-gcb
dlbcl appear preferenti treatment gcb subtyp
dlbcl although physician feedback suggest addit chemotherapi
 target bispecif antibodi blinatumomab may use
antibody-drug conjug brentuximab vedotin may use patient
provid simplifi approxim dlbcl patient treatment spectrum
although note treatment pattern becom nuanc highli variabl
exhibit illustr standard-of-car patient dlbcl current
new in-develop therapi dlbcl includ adc bispecif antibodi
briefli discuss exhibit list key data catalyst
tafasitamab antibodi current evalu use across
dlbcl chronic lymphocyt leukemia cll advanc tafasitamab
program l-mind studi base bla submit fda
decemb expect submit ema
 pdufa date bla grant prioriti review fda
addit tafasitamab previous obtain breakthrough therapi
design r/r dlbcl set combin lenalidomid data l-
mind studi present icml l-mind single-arm
open-label phii studi evalu tafasitamab lenalidomid patient r/r
dlbcl baselin characterist summar overal patient
widespread diseas mostli inelig hdc asct receiv prior
line therapi
exhibit baselin characterist l-mind studi tafasitamab lenalidomid r/r
prior line therapi
refractori last prior therapi
subgroup analys l-mind phase ii studi tafasitamab combin lenalidomid patient relaps refractori
l-mind includ tafasitamab lenalidomid phase cycl treatment
follow tafasitamab monotherapi cycl onward lenalidomid
discontinu common combin treatment
neutropenia thrombocytopenia leukopenia anemia
frequent observ lenalidomid treatment l-mind patient
requir lenalidomid dose reduct addit patient
discontinu combin therapi commonli due neutropenia
patient continu receiv tafasitamab monotherapi howev
common ae neutropenia major observ
combin seen significantli lower rate tafasitamab monotherapi
indic tafasitamab gener toler agent
summari key efficaci paramet l-mind studi provid
median follow-up month present overal find high
cr rate durabl highli encourag especi given
select efficaci paramet l-mind studi r/r dlbcl
median time respons month
median time cr month
median os reach median follow-up month os rate
subgroup analys l-mind phase ii studi tafasitamab combin lenalidomid patient relaps refractori
median dor cr patient
median dor pr patient
select subgroup data present summar believ key
takeaway tafasitamab activ gcb non-gcb subtyp dlbcl
appear activ non-gcb diseas although note subtyp
unknown patient studi await addit data real-world use
confirm find tafasitamab appear activ regardless whether patient
refractori last therapi tafasitamab appear efficaci
patient receiv fewer prior line therapi patient achiev cr
significantli better outcom achiev pr overal believ
subgroup analys indic potenti broad use tafasitamab also help
make case earlier vs later-lin use tafasitamab patient inelig hdc
refractori prior
prior line
subgroup analys l-mind phase ii studi tafasitamab combin lenalidomid patient relaps refractori
investor inquir increment benefit tafasitamab may
provid lenalidomid given l-mind studi includ activ control
arm given lenalidomid monotherapi previous demonstr anti-lymphoma
effect believ data re-mind studi support regard re-mind
morphosi cover announc top line data late octob
observ retrospect studi compar efficaci outcom non-
transplant elig r/r dlbcl patient receiv lenalidomid monotherapi
eu patient l-mind studi receiv tafasitamab
lenalidomid patient match accord baselin characterist
summar efficaci result disclos re-mind detail date
limit believ result gener support combin lead
robust outcom lenalidomid monotherapi
expect addit area investor focu tafasitamab profil relat
agent approv develop r/r dlbcl given emerg
competit natur space cross-trial comparison challeng
particularli due heterogen patient baselin characterist diseas
behavior trial design r/r dlbcl provid broad efficaci comparison
tafasitamab lenalidomid polivi bendamustin rituximab br selinexor
magrolimab polivi commerci roch cover mark
purcel selinexor develop karyopharm cover magrolimab
develop forti seven regeneron respect cover
approv
develop statu r/r dlbcl
prior line therapi median rang
entir set b-nhl patient data present
gener agent appear activ better understand efficaci profil
tafasitamab lenalidomid howev believ relev compar
polivi br selinexor three agent evalu patient
receiv median two prior line therapi mostli inelig
autolog sct data magrolimab present date
sever patient data set also early-stag
tafasitamab lenalidomid polivi br selinexor compar three
agent find key takeaway follow
selinexor may prove attract patient provid given
oral drug tafasitamab lenalidomid appear notabl effect
efficaci profil tafasitamab lenalidomid seem gener in-lin
polivi br
howev note polivi pivot studi appear enrol patient
popul sever diseas suggest polivi br could prove
potent tafasitamab lenalidomid real-world set
review data physician feedback strongli suggest addit
efficaci provid seek therapi present least risk toxic
easi administ lack complex administr consist cite
key consider drive uptak estim dlbcl patient treat
commun treatment center often fewer medic resourc academ
center kol feedback suggest use car-t like remain root
academ medic center physician commun center may find
tafasitamab lenalidomid easier regimen administ adc prefer
use versu bispecif antibodi pose risk neurotox howev
one aspect tafasitamab lenalidomid combin may act deterr
community-bas physician dose modif often requir due
lenalidomid toxic observ l-mind although expect bulk
commun center familiar lenalidomid given broad use multipl
overal believ tafasitamab lenalidomid strong efficaci data
manag ae profil rel eas use allow becom heavili use
dlbcl data set monitor throughout
data phiii studi evalu yescarta dlbcl vs
initi data phiii studi evalu magrolimab rituximab
r/r dlbcl patient fail prior line therapi
data phiii polarix studi evalu polivi r-chp vs r-
chop dlbcl
updat phi data dlbcl
potenti updat phi/ii studi mosunetuzumab
note gilead forti seven regeneron cover matthew harrison roch cover mark purcel
addit l-mind incyte/morphosi evalu tafasitamab r/r dlbcl
combin chemotherapi agent bendamustin b-mind studi
dlbcl combin r-chop phi first-mind studi
summari program provid morphosi announc
earn teleconfer phi first-mind data expect
result first-mind inform design potenti pivot studi believ
first-mind data repres key catalyst frame analyst investor
percept regard opportun tafasitamab front-lin dlbcl
morphosys/incyt also earli stage broad develop program
cll/nhl includ evalu combin tafasitamab
prior line therapi
asct failur patient inelig hdc asct
clear novemb
initi decemb
case mani biopharma compani believ could impact
disrupt delay relat outbreak impact jakafi sale
clear area investor focu also await incyt
manag commentari impact clinic regulatori catalyst
anticip throughout three key schedul catalyst
tafasitamab anticip submiss ema base
l-mind re-mind data fda decis tafasitamab r/r
dlbcl pdufa date data phib first-mind studi
evalu tafasitamab front-lin dlbcl
ruxolitinib cream detail true-ad phiii data mild-to-moder atop dermat ad
pdufa date fgfr inhibitor pemigatinib cholangiocarcinoma cca
submiss antibodi tafasitamab r/r dlbcl ema
pdufa date tafasitamab r/r dlbcl
phiii studi jakafi steroid-refractori chronic gvhd cgvhd
initi phiii studi evalu jakafi myelofibrosi mf
proof-of-concept data jakafi pim myelofibrosi mf
initi bioequival data once-a-day ruxolitinib
updat phii data pemigatinib bladder cancer
updat phii data parsaclisib non-hodgkin lymphoma nhl
phii data antibodi anal cancer
initi clinic data oral inhibitor solid tumor
ruxolitinib cream nda submiss ruxolitinib cream mild-to-moder ad
phib data first-mind studi evalu tafasitamab dlbcl
morphosi expect begin commerci tafasitamab
eu assum regulatori approv morphosi
earn teleconfer morphosi manag note impact current
expect bla file accept fda submiss
also remain track morphosi anticip manufactur
suppli issu could lead lack product avail launch
regulatori timelin appear schedul base case conserv assum
month commerci delay geographi account mani
uncertainti remain regard potenti impact result
base case assum launch eu launch morphosi
note enrol remain track phib first-mind studi
await futur manag commentari
incorpor ex-u project tafasitamab dcf
base case assign risk-adjust valu tafasitamab r/r dlbcl base l-mind
b-mind program current valu dlbcl assum tafasitamab
commerci begin eu row
project peak risk-adjust sale tafasitamab r/r dlbcl
ex-u model account term morphosi
partnership agreement call ex-u royalti morphosi
profit share beyond r/r dlbcl assign modest valu
tafasitamab broad develop program incyte/morphosi underway
peak profit peak sale ex-u aggreg tafasitamab
contribut valu model dlbcl current await
phi first-mind data better understand path forward tafasitamab
highlight could area signific valu creation posit path
develop exampl assum ww launch front-lin set
eventu patient share lead addit valu model
patient eventu r/r treatment
patient elig high-dos chemotherapi hdc
patient inelig high-dos chemotherapi hdc
patient receiv hdc elig sct
patient cure hdc sct
patient inelig hdc
patient elig hdc inelig asct
patient tafasitamab
patient eventu r/r treatment
patient elig high-dos chemotherapi hdc
patient inelig high-dos chemotherapi hdc
patient receiv hdc elig sct
patient cure hdc sct
patient inelig hdc
patient elig hdc inelig asct
patient tafasitamab
jaka perform late-stag pipelineprogress drive risk/reward
deriv price target discount cash ow analysi factor explicit
revenu project use discount rate termin growth
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
jaka sale surpass upper rang
jaka sale surpass upper rang
perform ruxolitinib cream
perform ruxolitinib cream
tafasitamab success dlbcl
tafasitamab success dlbcl
jaka sale peak total
revenu ruxolitinib cream
gener peak sale
across vitiligo atop dermat
tafasitamab gener total contribut
guidanc coupl strong pipelin
guidanc coupl strong pipelin
realiz jaka sale
manag long-term guidanc
peak total revenu
approv strong uptak
ruxolitinib cream vitiligo atop
dermat aggreg peak sale
tafasitamab gener total
contribut
overweight base
defens base busi valu provid
jaka mpnsand gvhd combin
option provid late-stag
pipelin key asset includ topic
jak inhibitor ruxolitinib cream
dlbcl believ investor expect
head key mileston
modest result nd risk/reward
skew upsid
jaka sale manag
jaka sale manag
guidanc modest royalti revenu
guidanc modest royalti revenu
sale peak royalti revenu
jaka ex-u olumi peak
iclusig sale aggreg peak
pipelin revenu
phiii data ruxolitinib steroid-refractori cgvhd
updat phii data pemigatinib bladder cancer
regulatori approv rux cream ad
phiii data vitiligo
clinic regulatori progress antibodi
data pemigatinib bladder cancer
detail jaka life cycl extens program
view explan region hierarchi
research highest favor quintil
greater pipelin realiz base case
project includ addit busi
long-term jaka sale perform
regulatori failurefor ruxolitinib cream ad
slow launch assum approv
clinic and/or regulatori failur tafasitamab
failur and/or minim success earlier-
stage program like pemigatinib
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
/share val
ruxolitinib cream detail true-ad phiii data mild-to-moder atop dermat ad
pdufa date fgfr inhibitor pemigatinib cholangiocarcinoma cca
submiss antibodi tafasitamab r/r dlbcl ema
pdufa date tafasitamab r/r dlbcl
phiii studi jakafi steroid-refractori chronic gvhd cgvhd
initi phiii studi evalu jakafi myelofibrosi mf
proof-of-concept data jakafi pim myelofibrosi mf
initi bioequival data once-a-day ruxolitinib
updat phii data pemigatinib bladder cancer
updat phii data parsaclisib non-hodgkin lymphoma nhl
phii data antibodi anal cancer
initi clinic data oral inhibitor solid tumor
ruxolitinib cream nda submiss ruxolitinib cream mild-to-moder ad
phib data first-mind studi evalu tafasitamab dlbcl
mileston contract revenu
cost expens
product revenu incl definite-liv intang amort
chang fair valu acquisition-rel conting consider
total cost expens
incom loss oper
unreal loss long-term invest
expens relat senior note convers
incom loss provis incom tax
provis incom tax
cash equival
prepaid expens current asset
restrict cash invest
properti equip net
accru current liabil
accumul comprehens incom
total liabil stockhold equiti
flow oper activ
in-process research develop
expens relat senior note convers
unreal loss long-term invest
chang fair valu acquisition-rel conting consider
chang oper asset liabil
prepaid expens asset
accru liabil
net cash provid use oper activ
flow invest activ
acquisit busi net cash acquir
purchas long-term invest
purchas market secur
sale matur market secur
net cash use invest activ
flow financ activ
proce issuanc common stock stock plan
proce issuanc common stock net
paid connect senior note convers
payment conting consider
net cash provid financ activ
effect exchang rate cash cash equival restrict cash invest
net increas cash cash equival restrict cash invest
cash equival restrict cash invest begin period
cash equival restrict cash invest end period
